Incannex Healthcare, Inc. 是一家生物技术公司,致力于开发大麻素和致幻化合物药物。该公司总部位于纽约州纽约市,目前拥有9名全职员工。公司于2022年3月18日首次公开募股(IPO)。该公司正在开发医用大麻素药物产品和致幻药物疗法,用于治疗阻塞性睡眠呼吸暂停(OSA)、创伤性脑损伤(TBI)和脑震荡、肺部炎症(ARDS、COPD、哮喘、支气管炎)、类风湿性关节炎、炎症性肠病、焦虑症、成瘾性疾病和疼痛等多种适应症。公司的多元化产品组合包括28个不同的研发(R&D)项目,以及正在进行的六项临床试验。其临床项目包括IHL-42X阻塞性睡眠呼吸暂停、IHL-675A炎症性肺部疾病、IHL-675A类风湿性关节炎、IHL-675A炎症性肠病、IHL-216A脑震荡和脑外伤、PSI-GAD裸盖菇素治疗焦虑症、MedChew GB带状疱疹后神经痛和MedChew-1401多发性硬化症的疼痛和痉挛。
IXHL stock price ended at $0.27 on 星期四, after dropping 3.57%
On the latest trading day Feb 12, 2026, the stock price of IXHL fell by 3.57%, dropping from $0.28 to $0.27. During the session, the stock saw a volatility of 11.54%, with prices oscillating between a daily low of $0.26 and a high of $0.29. On the latest trading day, the trading volume for IXHL rose by 1.6M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 4.3M shares were traded, with a market value of approximately $93.4M.